VJHemOnc Podcast Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease
May 30, 2025
Join Dr. Graham Collins from Oxford University Hospitals, a lymphoma expert, as he delves into groundbreaking treatments for Hodgkin lymphoma. He highlights the shift towards newer regimens like nivolumab-AVD and BV-AVD, showcasing their potential to improve patient outcomes. The discussion touches on the complexities of managing relapsed disease, emphasizing innovative strategies that may reduce reliance on stem cell transplants. Exciting insights into ongoing clinical trials further illuminate the future of Hodgkin lymphoma therapies.
AI Snips
Chapters
Transcript
Episode notes
PET-Adapted Approaches Advance Treatment
- PET-adapted treatment approaches in advanced-stage Hodgkin lymphoma allow fewer chemotherapy cycles with comparable cure rates.
- Newer regimens like nivolumab-AVD and BV-AVD show improved outcomes and reduced toxicity compared to traditional therapies.
ABVD Use in Special Cases
- ABVD still plays a role in early-stage Hodgkin lymphoma and special populations like pregnant patients.
- Avoid ABVD in advanced-stage disease where targeted regimens are available due to better survival and toxicity profiles.
Nivolumab-AVD Promises Better Outcomes
- Nivolumab-AVD demonstrates better progression-free survival and lower toxicity compared to AVD-Brentuximab.
- Older patients especially benefit from Nivo-AVD, filling an unmet need in frontline therapy.